Commencement of Replenishment of Govt Stockpiles of Oseltamivir and Zanamivir are just around the corner - the results of this study if timely could be a leg up for GSK and BTA royalties
Background Human infections with avian influenza A (H5N1) are associated with high mortality. As of July 5, 2010 there had been 500 cases and 296 fatalities. The influenza virus readily undergoes mutation and re-assortment, and there are concerns that an H5N1 variant could be responsible for a future pandemic. The influenza neuraminidase inhibitors Zanamivir and Oseltamivir are approved for the treatment and prophylaxis of influenza. Oseltamivir is being used to treat H5N1 infections and a case has been made supporting the use of Zanamivir also; however, there are no reports for the latter. Despite treatments with early use of oseltamivir combined with supportive care as suggested by WHO, 30% to 80% of hospitalized patients with H5N1 influenza have died, and an oseltamivir-resistant virus has developed in some patients.
BTA Price at posting:
89.5¢ Sentiment: LT Buy Disclosure: Held
